Navigation Links
Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
Date:5/19/2011

protein.  Multiple myeloma causes hypercalcemia, anemia, low platelet counts, increases the risk of infection and weakens the bones increasing the risk of fracture, pain, and disability.  Across the U.S. more than 20,000 new cases of multiple myeloma are reported each year, with approximately 10,500 deaths attributed to the disease annually.(1)

About Lilly Oncology

For more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated to delivering innovative solutions that improve the care of people living with cancer.  Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches.  To learn more about Lilly's commitment to cancer, please visit www.LillyOncology.com.  

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.  Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.

P-LLY

bortezomib, Velcade®, Millenium Pharmaceuticals

This press release contains forward-looking statements about the potential of LY2127399 and reflects Lilly's current beliefs. However, as with any pharmaceutical compound, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that this compound will be approved by the relevant regulatory authorities or prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
2. New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs
3. Study Shows Improved Patient Management and Outcome Using Abbotts Sensitive Troponin Assay
4. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
5. Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
6. Exploratory Efficacy Analysis Conducted for Long-Term Extension Study in Patients With Prostate Cancer Treated With FIRMAGON® or Crossed Over to FIRMAGON From Leuprolide
7. Caldolor® Clinical Study in Hospitalized Burn Patients Published in Journal of Burn Care & Research
8. Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052)
9. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
10. Kaiser Permanente Study Challenges Concerns on Effectiveness of Administering Pneumococcal & Shingles Vaccines Together
11. Star Scientific Files First Quarter Report, Updates Details of Flint Study Using RCP-006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... In the latest call for gender equity ... than 60 doctors and leading medical experts from across ... Food and Drug Administration,s (FDA) decision to approve 26 ... sexual dysfunction compared with ZERO for women,s most common ... women by approving the first-ever drug to treat Hypoactive ...
(Date:8/1/2014)... DALLAS , August 1, 2014 ... Care Market by Type (Traditional Wound Closure, Anti infective), ... Active (Artificial Skin & Skin Substitutes), Pressure Relief ... by MarketsandMarkets, the global Wound Care Market is expected ... Billion in 2014, growing at a CAGR of ...
(Date:8/1/2014)... PLYMOUTH MEETING, Pa. , Aug. 1, 2014 /PRNewswire/ ... that it will host a conference call to report ... 11, 2014 at 9:00 AM ET. CEO Dr. ... will discuss second quarter earnings, provide a corporate ... The update will include clinical development plans for VGX-3100, ...
Breaking Medicine Technology:60+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
... , CHANGCHUN, China and LOS ... Bulletin Board: CYXN) ("Yongxin" or,"the Company"), a leading pharmaceutical ... the third quarter ended,September 30, 2009. , ... products depend on discretionary,spending, we expect as the economy ...
... , MINNEAPOLIS, Dec. 10 Uroplasty, Inc. ... that develops, manufactures and markets innovative proprietary products to ... the OrBIT Trial of its Urgent® PC Neuromodulation System ... edition of THE JOURNAL OF UROLOGY® . The ...
Cached Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4
(Date:8/1/2014)... News) -- The U.S. Food and Drug Administration announced ... to help fight type 2 diabetes. Jardiance ... treatment regimens to control blood sugar levels in the ... the Office of Drug Evaluation II in the FDA,s ... agency statement. The FDA also recommended that Jardiance ...
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
(Date:8/1/2014)... 01, 2014 Growing prevalence of ... healthcare reforms are boosting healthcare market growth, although ... discounts and increasing generic consumption is a major ... million in 2013, having grown at a Compound ... The implementation of the Health Transformation Program (Saglikta ...
(Date:8/1/2014)... with the progressive, deadly respiratory ailment known as chronic ... battle the disease, the U.S. Food and Drug Administration ... treatment, an inhaled spray called Striverdi Respimat (olodaterol) for ... is often linked to smoking, involves multiple lung conditions ... with COPD may experience a number of symptoms, such ...
(Date:8/1/2014)... Abington, PA (PRWEB) August 01, 2014 ... beneficial than bottle-feeding. A recent study conducted ... may not lag too far behind in terms of ... simply want to know what’s best for their baby. ... , According to Dr. Steven Shapiro , chair ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3
... of the most aggressive cancers worldwide and its incidence is ... infection and aflatoxin contamination of foodstuffs. The cancer is also ... and China have been studying gene activity in liver tumors ... of detecting tumors that spread. They found that there is ...
... born during night time have a higher risk of ... day time. Previous studies have also shown that infants ... an increased risk of death at birth, urging the ... obstetric and neonatal care during the night. Researchers conducted ...
... been believed, over the years, to be a potential cure against ... true by researchers who have studied changes in immune cells' response ... 12 healthy subjects who took one gram of vitamin C a ... in all of them during the period. Their finding(in two patients) ...
... from The Forsyth Institute in Boston and the University of ... of the Journal of Microbiology that bad breath or halitosis ... back portion of the top of your tongue. The study ... the tongues of those with halitosis and those with fresh ...
... of the long-running Framingham Heart Study have now found ... levels of homocysteine, an amino acid whose build-up has ... and dementia, increases the risk of developing congestive heart ... age 72 years, who were studied during 1979 to ...
... researchers in the Journal of Hypertension indicates that ... improve their atherosclerotic risk profile by consuming alcohol ... serum lipoprotein(a), a powerful predictor of organ damage, ... studied 402 patients with untreated essential hypertension to ...
Cached Medicine News:Health News:Germs to blame for bad breath 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: